---
title: "Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Plasma exchange"
description: "Formulary evidence on Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Plasma exchange. Topics: Guideline recommendation after failure of immunoglobulin and corticosteroids, Pooled randomized evidence for plasma exchange, Plasma exchange versus sham exchange: parallel-group trial, and Plasma exchange versus sham exchange: double-blind crossover trial. 4 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description/plasma-exchange"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Plasma exchange

<a id="heading-2.2.2.1.4"></a>

## 2.2.2.1.4 Plasma Exchange

<a id="topic-2.2.2.1.4-1"></a>

### Guideline recommendation after failure of immunoglobulin and corticosteroids

> “(b) plasma exchange is strongly recommended if IVIg and corticosteroids are ineffective”

Source: [Van den Bergh et al. (2021)](https://onlinelibrary.wiley.com/doi/10.1111/ene.14959)

<a id="topic-2.2.2.1.4-2"></a>

### Pooled randomized evidence for plasma exchange

> “Primary outcome measure: one cross‐over trial including 18 participants showed after four weeks, 2 (95% confidence interval (CI) 0.9 to 3.1) points more improvement on an 11‐point disability scale with plasma exchange (10 exchanges over four weeks) than with sham exchange.”
> “Non‐randomised evidence indicates that plasma exchange induces adverse events in 3% to 17% of procedures.”
> “Adverse events related to difficulty with venous access, use of citrate, and haemodynamic changes are not uncommon.”

Source: [Mehndiratta et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6734114/)

<a id="topic-2.2.2.1.4-3"></a>

### Plasma exchange versus sham exchange: parallel-group trial

> “We performed a prospective double-blind trial in which patients with static or worsening disease were randomly assigned to plasma exchange (n = 15) or to sham exchange (n = 14) for three weeks.”
> “We conclude that for some patients with chronic inflammatory demyelinating polyradiculoneuropathy, plasma exchange has an ameliorating effect on neurologic dysfunction and nerve conduction, but in others no improvement is observed.”

Source: [Dyck et al. (1986)](https://pubmed.ncbi.nlm.nih.gov/3511382/)

<a id="topic-2.2.2.1.4-4"></a>

### Plasma exchange versus sham exchange: double-blind crossover trial

> “A primary 'intention to treat' analysis showed significant improvement with PE in all clinical outcome measures: NDS by 38 points, P < 0.001; CG by 1.6 points, P < 0.001; GS by +13 kg, P < 0.003”
> “We conclude that PE is a very effective adjuvant therapy for CIDP of both chronic progressive and relapsing course; concurrent immunosuppressive drug treatment is required.”
> “Exchange treatments should be given two to three times per week until improvement is established; the treatment frequency should then be tapered over several months.”

Source: [Hahn et al. (1996)](https://pubmed.ncbi.nlm.nih.gov/8813270/)

## Related pages
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: References](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references.md)
